[HTML][HTML] Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after …
A Freedman, SS Neelapu, C Nichols… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2009•ncbi.nlm.nih.gov
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T
and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With
Follicular Lymphoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC3646306 Other Formats PubReader PDF (185K) Actions Cite Collections Share …
and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With
Follicular Lymphoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC3646306 Other Formats PubReader PDF (185K) Actions Cite Collections Share …
Abstract
Purpose
To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD20+ follicular lymphoma.
ncbi.nlm.nih.gov